✦ LIBER ✦

The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype

✍ Scribed by Kenjiro Aogi; Masayuki Yoshida; Yoshiaki Sagara; Shunji Kamigaki; Minoru Okazaki; Jumpei Funai; Toshio Fujimoto; Masakazu Toi; Toshiaki Saeki; Shigemitsu Takashima

Publisher: Springer
Year: 2010
Tongue: English
Weight: 311 KB
Volume: 67
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-010-1390-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Final results of a phase II study ofnab-

Final results of a phase II study ofnab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

✍ Christopher Lobo; Gilberto Lopes; Odalys Baez; Aurelio Castrellon; Annapoorna Fe 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 268 KB

First-line bevacizumab in combination wi

First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study

✍ Kenjiro Aogi; Norikazu Masuda; Shinji Ohno; Takashi Oda; Hiroji Iwata; Masahiro 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 308 KB